Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without early targeted peripheral laser photocoagulation for macular edema due to central retinal vein occlusion
2020-000681-42Phase 3Active
- Sponsor
- Justus Liebig University Giessen
- Start
- Apr 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in central retinal vein occlusion (CRVO) and macular edema (2 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: Primary efficacy endpoint. Started Apr 2020; status: active.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion (CRVO)macular edema
Beyond the preview
Go deeper on 2020-000681-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000681-42.